Skip to main content

Published locations for FDA approves dabrafenib/trametinib for BRAF-positive anaplastic thyroid cancer

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA approves dabrafenib/trametinib for BRAF-positive anaplastic thyroid cancer

User login

  • Reset your password
  • /content/fda-approves-dabrafenib/trametinib-braf-positive-anaplastic-thyroid-cancer
  • /oncologypractice/article/165207/head-neck-cancers/fda-approves-dabrafenib/trametinib-braf-positive
  • /clinicalendocrinologynews/article/165207/head-neck-cancers/fda-approves-dabrafenib/trametinib-braf
  • /hematology-oncology/article/165207/head-neck-cancers/fda-approves-dabrafenib/trametinib-braf
  • /endocrinology/article/165207/head-neck-cancers/fda-approves-dabrafenib/trametinib-braf-positive